1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2015-2025

Report Details
Contracted drug production – stay ahead now by exploring leading companies’ prospects
How are pharma contract manufacturing organisations (CMOs) performing? Visiongain’s updated report shows you their prospects to 2025. You discover that outsourcing industry’s results, trends, opportunities and potentials, also with predicted revenues and profits.

Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. You explore trends, technologies and opportunities shaping that industry. Discover that market’s potential, benefiting your reputation for commercial insight.

That way you find analysis on established and emerging companies across the world. Read on, please, to scan the leading companies and see revenue prediction for their industry.

Forecasts and other data to help you stay ahead, benefiting your influence
In our new study you find analytical profiles of 30 top contractors, and analyses of their overall industry. You discover historical data, market and sales shares, growth rates and revenue forecasts. Also explore qualitative analyses, business outlooks and developments.

Our study gives you 185 tables, 111 charts and three interviews with companies.

That investigation also shows you prospects for these outsourced production segments at world level, including their overall revenue forecasts to 2025:
- Active pharmaceutical ingredients (API) production
- Finished dosage formulations (FDF) manufacturing.



In particular, biologics and biosimilars hold promise. New therapies – including antibody-drug conjugates, high potency APIs and regenerative medicines – increasingly interest CMOs and clients.

Discover, then, what the future holds. The following sections highlight what our research and analyses give you, to benefit planning, proposals and presentations.

Company profiles – explore commercial activities, results, competition and prospects
Our report analyses 30 leading companies. The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information:
- Overview of the company’s contract manufacturing services and operations
- Analysis of recent financial performance – annual revenue for CMO services, including some data on operating profit and margins
- Assessment of developments – activities, acquisitions, production capacity, deals, new service offerings and collaborations
- SWOT analysis – a firm’s strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2015 onwards
- Forecasting of pharmaceutical manufacturing revenue to 2025 (for 26 firms), as well as projected operating profit and margin for some companies.

Pharmaceutical developers, producers and marketers will increasingly use CMOs. With our study you discover what that industry’s participants offer – along with their trends and revenue potentials – helping you stay ahead in knowledge and benefit your authority.

European contract manufacturing organisations
Our study gives you discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms:
- Lonza
- Evonik Degussa
- Royal DSM
- Boehringer Ingelheim
- Fareva
- Famar
- Vetter Pharma.

Discover what the future holds for those pharma service providers, including revenue outlooks to 2025. What profitability and other achievements are possible?

CMOs based in the US and Japan
Our report also shows you developments and business outlooks for seven other international drug production contractors:
- Catalent Pharma Solutions
- Patheon
- Baxter BioPharma Solutions
- AbbVie Contract Manufacturing
- Pfizer CentreSource
- Daito Pharmaceutical
- Nipro Corporation.

Our work reveals where sales growth can occ

Table Of Contents

Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) - Market, Industry, Trends, Technologies and Prospects 2015-2025
Table of Contents
1. Report Overview
1.1 Leading Contract Manufacturing Organisations (CMOs) Overview
1.2 Benefits of This Report
1.3 How This Report Delivers Information
1.4 Main Questions This Report Answers
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Related Reports
1.9 About Visiongain
2. Introduction to Pharmaceutical Contract Manufacturing, 2015
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 Why Do Firms Outsource Manufacturing?
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market, 2014
2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
2.3 Outlook for the Pharmaceutical Contract Manufacturing Market 2015-2025
2.4 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2015-2025
2.4.1 Pharmaceutical Contract Manufacturing: Market Drivers 2015-2025
2.4.2 Pharmaceutical Contract Manufacturing: Market Restraints 2015-2025
2.5 Who Are the Leading Pharmaceutical Contract Manufacturers in 2014?
3. Leading CMOs in North America
3.1 Catalent Pharma Solutions- One of the World's Leading CMO
3.1.1 Catalent: Manufacturing Services and Capabilities
3.1.2 Divisional Segmentation - Breaking Down Catalent's Service
3.1.3 Catalent Pharma's Revenue Growth, 2010-2014
3.1.4 Sustained Growth in Oral Products: Catalent Pharma's Divisional Performance, 2010-2014
3.1.5 Catalent Is Expanding its Oral Technologies Division
3.1.6 Quadrupling Biopharmaceutical Manufacturing Capacity
3.1.7 Expansion of Packaging Services in Asia-Pacific and Europe: 2015
3.1.8 Adding New Early-Stage Development Services
3.1.9 Expansion in Japan - Growth Prospects for Catalent
3.1.10 New Business Contracts 2014-2015
3.1.11 Catalent New Products Launch
3.1.12 Catalent: Opportunities for Growth 2015-2025
3.1.13 Catalent: Mild Growth in Revenue, 2015-2025
3.2 Patheon - One of The Top 3 CMOs
3.2.1 Patheon - Global leader in Pharmaceutical Development Services
3.2.2 Contract Manufacturing Services at Patheon
3.2.3 Steady Revenue Growth 2010-2014
3.2.4 DPx Holdings: Developments
3.2.5 Adding New Formulations and Formulation Development Services
3.2.6 Reassessing Manufacturing Capacity
3.2.7 Expanding Services Through Acquisition, 2015
3.2.8 Patheon: SWOT Analysis 2015-2025
3.2.9 Patheon: Contract Manufacturing Revenue Forecast 2015-2025
3.3 Baxter BioPharma Solutions
3.3.1 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
3.3.2 Historic Revenue Performance 2010-2014
3.3.3 Baxter BioPharma SWOT Analysis 2015-2025
3.3.4 Baxter BioPharma Revenue Forecast 2015-2025
3.4 AbbVie Contract Manufacturing
3.4.1 AbbVie Offers Full-Service Contract Manufacturing
3.4.2 Expanding and Adding New Services: 2013-2014
3.4.3 AbbVie Contract Manufacturing: Revenue 2011-2014
3.4.4 Biologics and HPAPIs Are an Opportunity for Growth 2015-2025
3.4.5 AbbVie Contract Manufacturing Revenue Forecast 2015-2025
3.5 Pfizer CentreSource
3.5.1 Pfizer CentreSource: Historic Revenue Performance, 2010-2014
3.5.2 Will Pfizer Divest CentreSource?
3.5.3 Outlook for CentreSource: Revenue Forecast 2015-2025
4. Leading European Contract Manufacturing Organisations
4.1 Lonza
4.1.1 Lonza Is a Leader in Biologics Manufacturing
4.1.2 Lonza Contract Manufacturing and Development: 2010-2014
4.1.3 Investing in Advanced Biological Drug Sectors
4.1.4 The Promise of Antibody-Drug Conjugates (ADCs)
4.1.5 The Regenerative Medicine Future in Japan
4.1.6 Lonza: SWOT Analysis 2015-2025
4.1.7 Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2015-2025
4.2 Evonik Degussa
4.2.1 Investing in API and Drug Delivery Services
4.2.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2010-2014
4.2.3 Evonik Is a HPAPI Specialist
4.2.4 Evonik Continues to Grow Across All Segments
4.2.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
4.2.6 Evonik Degussa: Revenue Forecast 2015-2025
4.3 Royal DSM - The World's Leading CMO
4.3.1 Amplified Revenue Growth in Pharma Manufacturing 2010-2014
4.3.2 DSM Pharmaceuticals Products: Manufacturing Services 2010-2014
4.3.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
4.3.4 DPx Holdings: A New Pharma Leader
4.3.5 Investing in Biopharma Manufacturing
4.3.6 Expanding API Manufacturing
4.3.7 Generics and Biologics Are an Opportunity for Growth, 2014-2025
4.3.8 DSM Pharmaceuticals Products: Revenue Forecast 2015-2025
4.4 Boehringer Ingelheim Contract Manufacturing
4.4.1 Expanding Biopharmaceuticals Manufacturing Services in China
4.4.2 Production Through to Fill and Finished Biopharmaceuticals
4.4.3 A Track Record of Production for 29 Biopharma Products
4.4.4 Increasing Revenue from Contract Manufacturing, 2010-2014
4.4.5 Pulling Out of Small Molecule API Manufacturing
4.4.6 Expanding through New Services
4.4.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2015-2025
4.4.8 Boehringer Ingelheim: Revenue Forecast 2015-2025
4.5 Fareva
4.5.1 Fareva Has 35 Years' Manufacturing Experience
4.5.2 Revenue Growth through Acquisitions: 2010-2014
4.5.3 Fareva SWOT Analysis: 2015
4.5.4 Fareva Revenue Forecast: 2015-2025
4.6 Aenova Group
4.6.1 Acquisition of Haupt Creates European CMO Giant
4.6.2 Aenova's Ever Expanding Manufacturing Capacity
4.6.3 Aenova's Revenue 2010-2014: Organic Growth and Acquisitions
4.6.4 Aenova's Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2015
4.6.5 Becoming a Leading Contract Manufacturer: Aenova Revenue Forecast 2015-2025
4.7 Famar
4.7.1 Famar Is an Expert in Lyophilisation
4.7.2 Sustained Growth in Famar's Revenue: 2010-2014
4.7.3 Expanding European Operations
4.7.4 Further Site Acquisitions Are an Opportunity for Growth 2015-2025
4.7.5 How Will Famar Perform 2015-2025?
4.8 Vetter Pharmaceutical
4.8.1 Vetter is an Injectable Manufacturing Specialist
4.8.2 Rapidly Growing Revenue in the US and Germany: 2010-2014
4.8.3 Services, Collaborations and Differentiating Factors
4.8.4 Expanding Services in US and Asia
4.8.5 Biologics Are an Opportunity for Growth for Vetter 2015-2025
4.8.6 Vetter Outlook: Revenue Forecast 2015-2025
4.9 Almac Group
4.9.1 Almac's Manufacturing Services
4.9.2 Almac Outpaces the Market: 2011-2014
4.9.3 Almac Adding Capacity Globally
4.9.4 New Services Added 2012-2015
4.9.5 Almac Group: Contract Manufacturing Market Outlook 2015-2025
4.9.6 How Will Almac Group Perform 2015-2025?
4.10 Delpharm
4.10.1 Finished Dosage Form Manufacturing for Developed Markets
4.10.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2010-2014
4.10.3 Delpharm: Outlook and Prospects for Growth 2015-2025
4.10.4 Generics Will Drive Revenue Growth for Delpharm 2015-2025
4.11 Siegfried
4.11.1 Siegfried's Acquisitions, 2010-2014
4.11.2 Expanding Siegfried's Manufacturing Footprint Globally
4.11.3 Expanding High Potency API Capabilities
4.11.4 Siegfried: Financial Performance 2010-2014
4.11.5 Siegfried's Characteristics within the Contract Manufacturing Market: SWOT Analysis 2015
4.11.6 Continued Revenue Growth for Siegfried 2015-2025
4.12 Corden Pharmaceutical
4.12.1 CordenPharma Service Division
4.12.2 CordenPharma Emerging in the API Market
4.12.3 Investments in Highly Potent Capabilities
4.12.4 CordenPharma: SWOT Analysis 2015-2025
4.13 Recipharm
4.13.1 Contract Development and Manufacturing Services
4.13.2 Recipharm: Financial Performance 2010-2014
4.13.3 Recipharm Invests in Facility Expansion
4.13.4 Recipharm Growing in Development and Technology Market through Acquisitions
4.13.5 Recipharm: Opportunities for Growth 2015-2025
4.13.6 Outlook for Recipharm: Revenue Forecast 2015-2025
4.14 Aesica Pharmaceuticals
4.14.1 Aesica Manufactures APIs and Finished Dosage Forms
4.14.2 Acquisitions Drive Revenue Growth but Operational Margins Have Declined, 2010-2014
4.14.3 Partnering with Academia for Innovative Solutions
4.14.4 Growth through Acquisitions and Internal Expansion
4.14.5 Aesica: Opportunities for Expansion 2015-2025
4.14.6 Forecast Aesica Financial Performance, 2015-2025
5. Leading Japanese Pharma Contract Manufacturing Organisations
5.1 Nipro Corporation: Japan's Leading CMO
5.1.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
5.1.2 Nipro: Decline in Revenue But Increasing Operating Profits 2010-2014
5.1.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2015
5.1.4 Nipro Revenue and Profitability Forecast 2015-2025
5.2 Daito Pharmaceutical
5.2.1 Daito Has a Portfolio of More than 30 APIs
5.2.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2010-2014
5.2.3 Daito Is Well-Placed for Asian Market Growth - SWOT Analysis 2015-2025
5.2.4 Sustained Growth in Revenue and Operating Profit for Daito, 2015-2025
6. Leading Developed-Market API Specialists
6.1 Teva API
6.1.1 API Manufacturing Services
6.1.2 Teva API: Financial Performance 2010-2014
6.1.3 Building a Footprint in Mexico, India and China
6.1.4 Teva API: SWOT Analysis 2015
6.1.5 Outlook for Teva API: Revenue Forecast 2015-2025
6.2 Esteve Química
6.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
6.2.2 Expanding in The US, 2015
6.2.3 Esteve Química: SWOT Analysis 2015-2025
6.3 Euticals
6.3.1 Euticals Manufactures More than 200 APIs
6.3.2 Acquisitions Drive Growth 2010-2014
6.3.3 Adding Capacity for Finished Dosage Forms
6.3.4 Asian Expansion Is an Opportunity for Growth 2015-2025
6.3.5 Euticals: Revenue Forecast 2015-2025
7. Leading Chinese Pharmaceutical Contract Manufacturers
7.1 Zhejiang Hisun Pharmaceutical
7.1.1 API Manufacturing for Markets Worldwide
7.1.2 Zhejiang Hisun's Rapid Growth in API Revenue Grows, 2010-2014
7.1.3 Moving Into International Drug Marketing
7.1.4 Zhejiang Hisun: Opportunities for Growth 2015-2025
7.1.5 Zhejiang Hisun: Strong API Revenue Growth 2015-2025
7.2 Zhejiang Huahai Pharmaceuticals
7.2.1 Zhejiang Huahai Is a Market Leader Within The Antihypertensive API Market
7.2.2 Zhejiang Huahai: Contract Manufacturing Performance 2010-2014
7.2.3 Expanding in the US Generic Drugs Market
7.2.4 Zhejiang Huahai: SWOT Analysis, 2015
7.2.5 Zhejiang Huahai: Revenue Forecast, 2015-2025
7.3 Shandong Xinhua Pharmaceutical
7.3.1 Experience in APIs and Finished Dosage Forms
7.3.2 Shandong Xinhua: Strong Revenue Growth 2010-2014
7.3.3 Growing through Joint Ventures
7.3.4 Looking to Expand in the US and EU 2015-2025
7.3.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2015-2025
8. Leading Indian Pharmaceutical Contract Manufacturers
8.1 Aurobindo Pharma
8.1.1 API Manufacturing Services
8.1.2 Aurobindo Pharma: Steady Revenue Growth 2010-2014
8.1.3 Aurobindo Expanding Outside of Antibacterials
8.1.4 Aurobindo: Opportunities for Expansion 2015-2025
8.1.5 How Will Aurobindo's Contract Manufacturing Division Perform 2015-2025?
8.2 Divis Laboratories
8.2.1 Divis Laboratories and the Contract Manufacturing Industry
8.2.2 Divis Laboratories: A Rapidly Growing CMO, 2010-2014
8.2.3 Divis Laboratories: API Manufacturing Outlook 2015-2025
8.2.4 Divis Laboratories: API Manufacturing Revenue Forecast, 2015-2025
8.3 Dr. Reddy's Laboratories
8.3.1 API and FDF Manufacturing Services
8.3.2 Dr. Reddy's PSAI: Strong Revenue Growth 2010-2014
8.3.3 Advancing in Complex Drug Manufacturing
8.3.4 Expanding in the European Manufacturing Market
8.3.5 Dr. Reddy's PSAI Division: Revenue Forecast 2015-2025
9. Research Interviews from Our Industry Survey
9.1 Dr Michael Quirmbach, Vice President, Global Sales and Marketing, CPI, Corden Pharma
9.2 Mrs Marianne Spaene, Executive Vice President, Global Head Business Development, Sales and Marketing, Siegfried
9.3 Dr Prabuddha Kundu, Cofounder and Executive Director, PREMAS Biotech
10. Conclusions of the Study
10.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
10.2 Strategies for Growth: Prospects For Leading CMOs, 2015-2025
10.3 High Demand for Biopharmaceutical Manufacturing Services
10.4 Investing in Novel Technologies
10.5 Outlook for API Manufacturers

List of Tables
Table 1.1 Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2014
Table 1.2 Foreign Currency Exchange Rates Used: 2014 Average Exchange Rate to $US
Table 2.1 Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2015
Table 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2012-2014
Table 2.3 Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), 2013
Table 2.4 Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2013
Table 2.5 Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019 and 2025
Table 2.6 Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2014
Table 3.1 Catalent Details, 2015
Table 3.2 Catalent Facility Details, 2015
Table 3.3 Catalent Financial Performance: Revenue ($m), 2010-2014
Table 3.4 Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2014
Table 3.5 Catalent Financial Performance by Division: Revenue ($m), Annual Growth Rate (%), Revenue Share (%), CAGR (%), 2010-2014
Table 3.6 Catalent New Products Launch: New Products, Annual Growth (%), CAGR (%), 2012-2014
Table 3.7 Catalent Pharma SWOT Analysis, 2015
Table 3.8 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 3.9 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 3.10 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 3.11 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 3.12 Patheon Details, 2015
Table 3.13 Patheon Manufacturing Facilities, 2014
Table 3.14 Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 3.15 Patheon: SWOT Analysis, 2015
Table 3.16 Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 3.17 Baxter BioPharma Solutions Details, 2015
Table 3.18 Baxter BioPharma Solutions: Facilities and Services Offered, 2014
Table 3.19 Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 3.20 Baxter BioPharma Solutions SWOT Analysis, 2015
Table 3.21 Forecast Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 3.22 AbbVie Contract Manufacturing: Details, 2015
Table 3.23 AbbVie Contract Manufacturing Facility Capabilities, 2014
Table 3.24 AbbVie Pharmaceutical Manufacturing: Revenue ($m) Annual Growth Rate (%), CAGR (%), 2011-2014
Table 3.25 AbbVie Contract Manufacturing SWOT Analysis, 2015
Table 3.26 Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 3.27 Pfizer CentreSource Details, 2015
Table 3.28 Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 3.29 Pfizer CentreSource SWOT Analysis, 2015
Table 3.30 Forecast Pfizer CentreSource Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 4.1 Lonza Details, 2015
Table 4.2 Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2015
Table 4.3 Lonza Pharma and Biotech Department: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2010-2014
Table 4.4 ADCs Approved and in Late Stage Clinical Development, 2014
Table 4.5 Lonza SWOT Analysis, 2015
Table 4.6 Forecast Lonza Pharma and Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2014-2019
Table 4.7 Forecast Lonza Pharma and Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2019-2025
Table 4.8 Evonik Degussa Details, 2015
Table 4.9 Evonik Health and Nutrition: RandD and Production Sites by Region, 2014
Table 4.10 Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.11 Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2015
Table 4.12 Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.13 Royal DSM Details, 2015
Table 4.14 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.15 DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.16 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.17 DSM Pharmaceutical Manufacturing: SWOT Analysis, 2015
Table 4.18 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2019
Table 4.19 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2019-2025
Table 4.20 Boehringer Ingelheim Biopharmaceuticals Details, 2015
Table 4.21 Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2014
Table 4.22 Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
Table 4.23 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2014
Table 4.24 Boehringer Ingelheim: SWOT Analysis, 2015
Table 4.25 Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.26 Fareva Details, 2015
Table 4.27 Fareva Manufacturing Facilities, 2014
Table 4.28 Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 4.29 Fareva: SWOT Analysis, 2015
Table 4.30 Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.31 Aenova Group Details, 2015
Table 4.32 Aenova Group Manufacturing Capacity by Dosage Form, 2015
Table 4.33 Aenova Group Manufacturing Facility Details, 2015
Table 4.34 Aenova Group Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
Table 4.35 Aenova Group SWOT Analysis, 2015
Table 4.36 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2014-2019
Table 4.37 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2019-2025
Table 4.38 Famar Details, 2015
Table 4.39 Famar Pharmaceutical Manufacturing Facilities, 2014
Table 4.40 Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 4.41 Famar: SWOT Analysis, 2015
Table 4.42 Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.43 Vetter Details, 2015
Table 4.44 Vetter Pharmaceutical Manufacturing Facilities, 2014
Table 4.45 Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 4.46 Vetter: SWOT Analysis, 2015
Table 4.47 Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.48 Almac Details, 2015
Table 4.49 Almac Pharmaceutical Manufacturing Facilities Details, 2014
Table 4.50 Almac Pharmaceutical Manufacturing: Revenue ($m), 2011-2014
Table 4.51 Almac: SWOT Analysis, 2015
Table 4.52 Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2014-2019
Table 4.53 Forecast Almac Pharmaceuticals: Revenue ($m), 2019-2025
Table 4.54 Delpharm Details, 2015
Table 4.55 Delpharm: Facilities and Services, 2014
Table 4.56 Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 4.57 Delpharm: SWOT Analysis, 2015
Table 4.58 Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2014-2025
Table 4.59 Siegfried Details, 2015
Table 4.60 Siegfried Pharmaceutical Manufacturing Facilities Details, 2015
Table 4.61 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 4.62 Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 4.63 Siegfried: SWOT Analysis, 2015
Table 4.64 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2014-2019
Table 4.65 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2019-2025
Table 4.66 CordenPharma Details, 2015
Table 4.67 CordenPharma Facilities and Service Details, 2014
Table 4.68 Corden Pharmaceuticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2014
Table 4.69 Corden Pharmaceuticals SWOT Analysis, 2015
Table 4.70 Recipharm Details, 2015
Table 4.71 Recipharm: Facility Details and Services, 2014
Table 4.72 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 4.73 Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2014
Table 4.74 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2014
Table 4.75 Recipharm: SWOT Analysis, 2015
Table 4.76 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2014-2019
Table 4.77 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2019-2025
Table 4.78 Aesica Details, 2015
Table 4.79 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2014
Table 4.80 Aesica SWOT Analysis, 2015
Table 4.81 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2014-2019
Table 4.82 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2019-2025
Table 5.1 Nipro Pharma Details, 2015
Table 5.2 Nipro Pharmaceutical Contract Manufacturing Capabilities: 2009-2014
Table 5.3 Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2014
Table 5.4 Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2010-2014
Table 5.5 Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2015
Table 5.6 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 5.7 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 5.8 Daito Pharmaceuticals: Details, 2015
Table 5.9 Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (Â¥m), Operating Profit ($m), Operating Profit (Â¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2010-2014
Table 5.10 Daito Pharmaceuticals SWOT Analysis, 2015
Table 5.11 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 5.12 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 6.1 Teva API Details, 2015
Table 6.2 Teva API: Site Acquisitions, 1980- 2011
Table 6.3 Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 6.4 Teva API SWOT Analysis, 2015
Table 6.5 Forecast Teva API Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 6.6 Esteve Química Details, 2015
Table 6.7 Esteve Química SWOT Analysis, 2015
Table 6.8 Euticals Details, 2015
Table 6.9 Euticals Facility Details: Production Capacity (m3) and Key Products, 2015
Table 6.10 Euticals Cumulative Regulatory Filings by Region/Country: Filings, Share of Total (%), 2014
Table 6.11 Euticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 6.12 Euticals Revenue by Product Class: Revenue ($m), Share of Total (%), 2014
Table 6.13 Euticals Revenue by Region: Revenue ($m), Share of Total (%), 2014
Table 6.14 Euticals SWOT Analysis, 2015
Table 6.15 Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 7.1 Zhejiang Hisun Pharmaceuticals Details, 2015
Table 7.2 Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 7.3 Zhejiang Hisun Manufacturing: SWOT Analysis, 2015
Table 7.4 Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 7.5 Zhejiang Huahai Pharmaceuticals Details, 2015
Table 7.6 Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 7.7 Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2015
Table 7.8 Forecast Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 7.9 Shandong Xinhua Pharmaceuticals Details, 2015
Table 7.10 Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2015
Table 7.11 Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 7.12 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2014
Table 7.13 Shandong Xinhua Manufacturing: SWOT Analysis, 2015
Table 7.14 Forecast Shandong Xinhua Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 8.1 Aurobindo Pharma Details, 2015
Table 8.2 Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 8.3 Aurobindo Contract Manufacturing Revenue by API Class: Revenue ($m), Revenue Share (%), 2014
Table 8.4 Aurobindo Contract Manufacturing: SWOT Analysis, 2015
Table 8.5 Forecast Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 8.6 Divis Laboratories Details, 2015
Table 8.7 Divis Laboratories: Facility Details, Production Capacity and Services, 2015
Table 8.8 Divis Laboratories: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 8.9 Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2014
Table 8.10 Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2014
Table 8.11 Divis Laboratories Contract Manufacturing: SWOT Analysis, 2015
Table 8.12 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m),EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 8.13 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 8.14 Dr. Reddy's Laboratories Details, 2015
Table 8.15 Dr. Reddy's Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 1987-2014
Table 8.16 Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 8.17 Dr. Reddy's Laboratories Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), FY 2014
Table 8.18 Dr. Reddy's Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2014
Table 8.19 Dr. Reddy's Laboratories: SWOT Analysis, 2015
Table 8.20 Forecast Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 10.1 Top Five Developed and Emerging Market CMOs: Grouped Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2010-2014
Table 10.2 CMOs by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2010-2014
Table 10.3 Leading CMOs: Combined Annual Revenue ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2014-2025
Table 10.4 Top Five Developed and Emerging Market CMOs: Grouped Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 10.5 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2014-2019
Table 10.6 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2019-2025

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

North America Insulin Delivery Market Outlook to 2022

North America Insulin Delivery Market Outlook to 2022

  • $ 5995
  • Industry report
  • January 2017
  • by Global Data

North America Insulin Delivery Market Outlook to 2022 Summary GlobalData’s new report, "North America Insulin Delivery Market Outlook to 2022", provides key market data on the North America Insulin Delivery ...

North America Vision Care Market Outlook to 2022

North America Vision Care Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

North America Vision Care Market Outlook to 2022 Summary GlobalData’s new report, "North America Vision Care Market Outlook to 2022", provides key market data on the North America Vision Care market. ...


Download Unlimited Documents from Trusted Public Sources

Pharmaceutical Market Size in the UK and the US

  • January 2017
    2 pages
  • Pharmaceutical  

    Bookstore  

  • United Kingdom  

    United States  

View report >

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Anti-Infective and Antidiabetics Market in India

  • January 2017
    21 pages
  • Anti-Infective  

  • India  

View report >

Diabetes Statistics

2 days ago

Related Market Segments :

Pharmaceutical

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.